|
10088
|
Weisairuiji Biovac-A Mevac-A
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Biogenetech Co. Ltd., Zhejiang Pukang Biotechnology Co. Ltd.
|
2010
|
Thailand
|
1.5 years and above
|
Single dose
|
Subcutaneous
|
NA
|
H2 strain of HAV
|
H2-attenuated strain of HAV cultured in human diploid cells.
|
China FDA, US FDA
|
NA
|
NA
|
MEVAC-A
|
24280971
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130259/
|
https://apps.who.int/iris/bitstream/handle/10665/326501/97892516327-eng.pdf
|
|
10089
|
Weisairuiji Biovac-A Mevac-A
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Institute of Medical Biology, Chinese Academy of Medical Sciences
|
NA
|
China
|
NA
|
Single dose
|
Subcutaneous
|
NA
|
H2 strain of HAV
|
NA
|
China FDA, US FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.fda.moph.go.th/sites/drug/Shared%20Documents/Vaccine/U1DR1C1072530000811C-SPC.pdf
|
|
10090
|
HAVAC
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Changchun Institute of Biological Products
|
NA
|
China
|
NA
|
Single dose
|
Subcutaneous
|
NA
|
LA-1
|
NA
|
Government of Canada
|
Changchun Changsheng Life Sciences
|
NA
|
NA
|
24280971
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130259/
|
https://www.canada.ca/en/public-health/services/publications/healthy-living/update-recommended-use-hepatitis-b-vaccine.html
|
|
10091
|
HAVAC
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Changchun Institute of Biological Products
|
NA
|
China
|
NA
|
Single dose
|
Subcutaneous
|
NA
|
LA-1
|
NA
|
Government of Canada
|
Changchun Changsheng Life Sciences
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.canada.ca/en/public-health/services/publications/healthy-living/update-recommended-use-hepatitis-b-vaccine.html
|
|
10092
|
HAVRIX
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
Belgium
|
NA
|
P: 720 EU; Adults: 1440 EU; 2 doses 0, 6–12
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
HM-175
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert---HAVRIX.pdf
|
|
10093
|
VAQTA
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Merck & Co. Inc.
|
NA
|
USA
|
NA
|
P: 25 U; Adults: 50 U; 2 doses 0, 6–18
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
CR-326
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/vaqta
|
|
10094
|
AVAXIM
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
Lyon, France
|
NA
|
P: 80 U; Adults: 160 U
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
GBM
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.fda.moph.go.th/sites/drug/Shared%20Documents/Vaccine/U1DR1C1062460010911C-SPC.pdf
|
|
10095
|
Healive
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sinovac Biotech Ltd.
|
NA
|
China
|
NA
|
P: 250 U; Adults: 500 U
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
TZ-84
|
NA
|
China FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
http://www.sinovac.com/news/shownews.php?id=764&lang=en
|
|
10096
|
Weisairuiji Biovac-A Mevac-A
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Institute of Medical Biology, Chinese Academy of Medical Sciences
|
NA
|
China
|
NA
|
P: 320 EU; Adults: 640 EU
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
Lv-8
|
NA
|
China FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482852/
|
|
10097
|
Veraxim
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Shanghai Wilson Bioengineering
|
NA
|
China
|
NA
|
P: 800 EU; Adults: 1600 EU
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
YN-5
|
NA
|
Government of China
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
|
10098
|
HAVRIX
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
Belgium
|
12 months and above
|
Single dose for adult and 2 doses 6 to 12 months apart for infants
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hav/havfaq.htm#vaccine
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/havrix
|
|
10099
|
VAQTA
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Merck & Co. Inc.
|
NA
|
USA
|
12 months and above
|
2 doses 6 to 18 months apart
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hav/havfaq.htm#vaccine
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/vaqta
|
|
10100
|
TWINRIX
|
Hepatitis A, Hepatitis B
|
Hepatitic
|
Hepatitis A, Hepatitis B virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
Rixensart, Belgium
|
18 years and above
|
3 doses at regimen of 0, 1, and 6 months
|
Intramuscular
|
Aluminum
|
Strain HM175, HBsAg
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hav/havfaq.htm#vaccine
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/twinrix
|
|
10101
|
ENGERIX-B
|
Hepatitis B
|
Hepatitic
|
Hepatitis B virus
|
double stranded DNA
|
DNA based vaccine
|
Approved
|
GlaxoSmithKline
|
NA
|
Rixensart, Belgium
|
All age group
|
3 doses at regimen of 0, 1, and 6 months
|
Intramuscular
|
NA
|
HBsAg
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/engerix-b
|
|
10102
|
RECOMBIVAX HB
|
Hepatitis B
|
Hepatitic
|
Hepatitis B virus
|
double stranded DNA
|
Protein subunit
|
Approved
|
Merck & Co. Inc.
|
NA
|
USA
|
All age group
|
2 doses 6 months apart
|
Intramuscular
|
NA
|
HBsAg
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/recombivax-hb
|
|
10103
|
HEPLISAV-B
|
Hepatitis B
|
Hepatitic
|
Hepatitis B virus
|
double stranded DNA
|
Subunit vaccine
|
Approved
|
Dynavax
|
NA
|
NA
|
18 years and above
|
2 doses 1 month apart
|
Intramuscular
|
CpG
|
HepB
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/heplisav-b
|
|
10104
|
PEDIARIX
|
Hepatitis B, Diphtheria, Tetanus, Acellular pertussis , Poliomyelitis
|
Hepatitic
|
Hepatitis B virus
|
double stranded DNA
|
NA
|
Approved
|
GlaxoSmithKline
|
NA
|
USA
|
6 weeks - 7 years
|
2 doses 6 months apart
|
Intramuscular
|
NA
|
HBsAg
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/pediarix
|
|
10105
|
HBVaxPRO
|
Hepatitis B
|
Hepatitic
|
Hepatitis B virus
|
double stranded DNA
|
Subunit vaccine
|
Approved
|
Sanofi Pasteur
|
NA
|
USA
|
18 years and above
|
NA
|
Intramuscular
|
NA
|
HBsAg
|
NA
|
EMA
|
NA
|
NA
|
NA
|
26208678
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685678/
|
https://www.ema.europa.eu/en/documents/overview/hbvaxpro-epar-summary-public_en.pdf
|
|
10106
|
Fendrix
|
Hepatitis B
|
Hepatitic
|
Hepatitis B virus
|
double stranded DNA
|
NA
|
Approved
|
GlaxoSmithKline
|
NA
|
Belgium
|
NA
|
NA
|
Intradermal, Intravenous
|
AS043
|
HBsAg
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
26208678
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685678/
|
https://www.ema.europa.eu/en/medicines/human/EPAR/fendrix
|
|
10107
|
Hecolin (Hepatitis vaccine -239)
|
Hepatitis E
|
Hepatitic
|
Hepatitis E virus
|
double stranded DNA
|
Virus like particle
|
Approved
|
Xiamen Innovax Biotech
|
2011
|
China
|
NA
|
3 doses at regimen of 0, 1, and 6 months
|
Intramuscular
|
NA
|
HEV-1 Chinese strain
|
NA
|
China FDA
|
NA
|
NA
|
NA
|
27610014
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4988308/
|
https://www.precisionvaccinations.com/vaccines/hecolin-hepatitis-e-vaccine
|
|
10108
|
Hecolin (Hepatitis vaccine -239)
|
Hepatitis E
|
Hepatitic
|
Hepatitis E virus
|
double stranded DNA
|
Recombinant viral vector
|
Approved
|
Xiamen Innovax Biotech
|
2011
|
China
|
NA
|
3 doses at regimen of 0, 1, and 6 months
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
Capsid Protein ORF2
|
NA
|
China FDA
|
NA
|
NA
|
Hecolin
|
29546064
|
NCT01014845
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818934/
|
https://www.precisionvaccinations.com/vaccines/hecolin-hepatitis-e-vaccine
|
|
10109
|
AMBIRIX
|
Hepatitis A, Hepatitis B
|
Hepatitic
|
Hepatitis A, Hepatitis B virus
|
double stranded DNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
2002
|
Belgium
|
1 - 15 years
|
2 doses 6 to 12 months apart
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
Inactivated hepatitis A virus and surface antigen of hepatitis B virus
|
Produced on human diploid (MRC-5) cells
|
EMA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.ema.europa.eu/en/documents/product-information/ambirix-epar-product-information_en.pdf
|
https://www.ema.europa.eu/en/documents/product-information/ambirix-epar-product-information_en.pdf
|
|
10110
|
AMBIRIX
|
Hepatitis A, Hepatitis B
|
Hepatitic
|
Hepatitis A, Hepatitis B virus
|
double stranded DNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
2002
|
Belgium
|
2 - 15 years
|
2 doses 6 to 12 months apart
|
Intramuscular
|
Aluminum (aluminum phosphate)
|
Inactivated hepatitis A virus and surface antigen of hepatitis B virus
|
Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology
|
EMA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.ema.europa.eu/en/documents/product-information/ambirix-epar-product-information_en.pdf
|
https://www.ema.europa.eu/en/documents/product-information/ambirix-epar-product-information_en.pdf
|
|
10111
|
VIVAXIM
|
Hepatitis A, Typhoid
|
Hepatitic
|
Hepatitis A virus, Salmonella typhi
|
double stranded DNA
|
NA
|
Approved
|
Sanofi Pasteur
|
2007
|
France
|
16 years and above
|
Single dose
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
Salmonella typhi Vi polysaccharide (Ty 2 strain) and formaldehyde inactivated hepatitis A virus antigen (GBM strain)
|
GBM strain cultured on MRC-5 human diploid cells
|
Government of Canada
|
NA
|
NA
|
VIATIM
|
NA
|
NA
|
http://products.sanofi.com.au/vaccines/VIVAXIM_NZ_PI.pdf
|
https://pdf.hres.ca/dpd_pm/00032177.PDF
|
|
10296
|
rHEV
|
Hepatitis E
|
Hepatitic
|
Hepatitis E virus
|
double stranded DNA
|
Recombinant viral vector
|
Phase 2
|
GlaxoSmithKline
|
2011
|
USA
|
18 - 58 years
|
3 doses at regimen of 0, 1, and 6 months
|
NA
|
Aluminum (alum)
|
Capsid Protein ORF2
|
NA
|
NA
|
National Institute of Health, Novavax
|
NA
|
NA
|
NA
|
NA
|
https://www.who.int/immunization/sage/meetings/2014/october/4_Hepatitis_E_vaccine_pipeline_final_29_Sept_14.pdf
|
NA
|
|
10366
|
EPAXAL
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Crucell, Berna Biotech
|
NA
|
Berne, Switzerland
|
NA
|
P: 24 U; Adults: 24 U
|
Intramuscular
|
NA
|
RG-SB
|
NA
|
NA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
NA
|
|
10367
|
Aimugen
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Chemo-Sero-Therapeutic Research Institute
|
NA
|
Japan
|
NA
|
P: 0.5 µg; Adults: 0.5 µg
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
KRM003
|
NA
|
NA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
NA
|
|
10368
|
Hepatyrix
|
Hepatitis A, Typhoid
|
Hepatitic
|
Hepatitis A virus, Salmonella typhi
|
double stranded DNA
|
Inactivated
|
Phase 3
|
Sanofi Pasteur
|
2015
|
Belgium
|
15 years and above
|
Single dose
|
Intramuscular
|
NA
|
Hepatitis A viral protein along with Vi polysaccharide antigen (a part of the Salmonella typhi (Ty2 strain) bacterium
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.hpra.ie/img/uploaded/vaccines/PIL_PA1077099001.pdf
|
NA
|